Short answer
4D Molecular Therapeutics, Inc. (FDMT) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results covered the three months ended June 30, 2026.
4D Molecular Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results covered the three months ended June 30, 2026
- Press release includes operational highlights and expected upcoming milestones
- Financial figures and management commentary available in the furnished exhibit
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss widened to $72.9M from $54.7M as R&D rose to $68.3M for Phase 3 wet AMD trials
- Cash, equivalents and marketable securities declined to $430.6M from $514.0M, with runway projected into H2 2028
- Hercules credit facility provides up to $200M, including an initial $20M draw, extending financing flexibility
- 4FRONT-1 enrollment completed with N=523; topline data expected Q2 2027
- 4FRONT-2 enrollment completed with N>500 expected randomized; topline data expected H2 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other 4D Molecular Therapeutics, Inc. 8-K filings
Get the next FDMT 8-K as it lands
Follow FDMT for push alerts, or ask the research agent what this filing means.